Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 0.01%, near the low end of its 5-year range (0.00%–21.11%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 7.41%.
Reported quarterly debt to assets ratio; no daily interpolation. Q1 FY2027 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
7.41%
DEBT TO ASSETS RATIO AVG 3Y
0.02%
DEBT TO ASSETS RATIO AVG 5Y
0.01%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 595 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Helus Pharma Inc.
Market Cap
$654.55M
Debt to Assets Ratio
0.00%
TTM Avg
7.41%
3Y Avg
0.02%
5Y Avg
0.01%
Market Cap
$651.36M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$664.86M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$636.13M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$676.27M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$616.53M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$700.94M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $654.55M | 0.00% | 7.41% | 0.02% | 0.01% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $651.36M | 0.08% | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $662.91M | 0.10% | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $664.86M | 0.01% | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $636.13M | 0.05% | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $676.27M | 0.00% | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $625.03M | 0.01% | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $616.53M | 0.00% | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $700.94M | 0.01% | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $606.21M | 0.01% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
10.97
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 15.94% |
| 2025-06-30 | 21.11% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.05% |
| 2024-06-30 | 0.07% |
| 2024-03-31 | 0.10% |
| 2023-12-31 | 0.28% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.18% |
| 2020-10-31 | 0.00% |
| 2020-06-30 | 0.00% |
| 2019-01-31 | 0.00% |
| 2018-07-31 | 0.00% |
| 2018-01-31 | 0.00% |
| 2017-10-31 | 0.00% |
